BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, De Hertogh G, Vermeire S. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab032. [PMID: 33624092 DOI: 10.1093/ibd/izab032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Bertani L. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. JCM 2022;11:5267. [DOI: 10.3390/jcm11185267] [Reference Citation Analysis]
2 Bourgonje AR, Wichers SJ, Hu S, van Dullemen HM, Visschedijk MC, Faber KN, Festen EAM, Dijkstra G, Samsom JN, Weersma RK, Spekhorst LM. Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease. Sci Rep 2022;12:14581. [PMID: 36028644 DOI: 10.1038/s41598-022-17504-5] [Reference Citation Analysis]
3 Borren NZ, Ananthakrishnan AN. Precision medicine: how multiomics will shape the future of inflammatory bowel disease? Curr Opin Gastroenterol 2022;38:382-7. [PMID: 35762697 DOI: 10.1097/MOG.0000000000000847] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yuan S, Wang Q, Li J, Xue JC, Li Y, Meng H, Hou XT, Nan JX, Zhang QG. Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment. Chin Med 2022;17:74. [PMID: 35717380 DOI: 10.1186/s13020-022-00633-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li Y, Yang X, Yuan J, Lin R, Tian Y, Li Y, Zhang Y, Wang X, Xie Y, Wang S, Zheng X. Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway. Front Pharmacol 2022;13:819826. [DOI: 10.3389/fphar.2022.819826] [Reference Citation Analysis]
6 Zhou G, Chen R, Jiang Y, Li L, Zheng J, Li C, Zhang S, Chen M. Development and validation of a non-invasive biomarker-based model to identify endoscopic recurrences of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210890. [DOI: 10.1177/17562848221089096] [Reference Citation Analysis]
7 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Reference Citation Analysis]
8 Martín-Hernández D, Gutiérrez IL, González-Prieto M, MacDowell KS, Robledo-Montaña J, Tendilla-Beltrán H, Calleja-Rodríguez N, Bris ÁG, Ulecia-Morón C, Moreno B, Caso JR, García-Bueno B, Rodrigues-Mascarenhas S, Marín-Jiménez I, Leza JC, Menchén L. Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon inflammation induced by sub-chronic stress. Sci Rep 2022;12:4073. [PMID: 35260749 DOI: 10.1038/s41598-022-08011-8] [Reference Citation Analysis]
9 Lindkvist M, Zegeye MM, Grenegård M, Ljungberg LU. Pleiotropic, Unique and Shared Responses Elicited by IL-6 Family Cytokines in Human Vascular Endothelial Cells. Int J Mol Sci 2022;23:1448. [PMID: 35163371 DOI: 10.3390/ijms23031448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Guo A, Ross C, Chande N, Gregor J, Ponich T, Khanna R, Sey M, Beaton M, Yan B, Kim RB, Wilson A. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Sci Rep 2022;12:1185. [PMID: 35075155 DOI: 10.1038/s41598-022-05208-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Cao Y, Dai Y, Zhang L, Wang D, Hu W, Yu Q, Wang X, Yu P, Liu W, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin. J Inflamm Res 2021;14:6409-19. [PMID: 34880643 DOI: 10.2147/JIR.S342846] [Reference Citation Analysis]
12 Rawle DJ, Dumenil T, Tang B, Bishop CR, Yan K, Le TT, Suhrbier A. Microplastic consumption induces inflammatory signatures in the colon and prolongs a viral arthritis. Sci Total Environ 2021;809:152212. [PMID: 34890673 DOI: 10.1016/j.scitotenv.2021.152212] [Reference Citation Analysis]
13 Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, Wang X, Yu P, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem 2021:S0009-9120(21)00310-6. [PMID: 34843732 DOI: 10.1016/j.clinbiochem.2021.11.011] [Reference Citation Analysis]
14 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Reference Citation Analysis]
15 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
17 Tsui FWL, Lin A, Sari I, Zhang Z, Tsui HW, Inman RD. Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis. Arthritis Res Ther 2021;23:141. [PMID: 33990221 DOI: 10.1186/s13075-021-02521-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]